Andrés Redondo
Hospital Universitario La Paz · Hospital La Paz
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrés Redondo as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:19 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05131386 · Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic SarcomasGrupo Espanol de Investigacion en Sarcomas · unknown · Soft Tissue Sarcoma, Bone Tumors, Small Round-cell Sarcomas · principal investigator
- Ph1/Ph2NCT03277924 · Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone SarcomasGrupo Espanol de Investigacion en Sarcomas · completed · Soft Tissue Sarcoma, Bone Sarcoma · principal investigator
- Ph2NCT03242382 · Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.Grupo Espanol de Investigacion en Sarcomas · unknown · Soft-tissue Sarcoma, Osteosarcoma, Chordoma · principal investigator
- Ph2NCT02101684 · Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.Grupo Español de Tumores Huérfanos e Infrecuentes · terminated · Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors · principal investigator
- Ph2NCT02066285 · Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid ChondrosarcomaGrupo Espanol de Investigacion en Sarcomas · completed · Solitary Fibrous Tumor, Extraskeletal Myxoid Chondrosarcoma · principal investigator
- Ph2NCT01246440 · Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease RemissionGrupo Español de Investigación en Cáncer de Ovario · completed · Ovarian Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:19 UTC. The ranking covers the 200 most relevant of 51 PubMed records, and a shared surname and initials can bring in a namesake. All 51 on PubMed
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.N Engl J Med · 20192,077 citationsRCR 85.1
- 2,017 citationsRCR 64.0
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.N Engl J Med · 20191,854 citationsRCR 69.4
- 368 citationsRCR 20.6
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.Lancet Oncol · 2014233 citationsRCR 6.3
- Safety and dose modification for patients receiving niraparib.Ann Oncol · 2018162 citationsRCR 4.8
- 162 citationsRCR 18.5
- Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial.J Immunother Cancer · 2020160 citationsRCR 6.7
- Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.N Engl J Med · 2025129 citationsRCR 30.4
- 124 citationsRCR 9.7